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ABSTRACT
Brain metastasis is a major cause of morbidity and mortality of lung cancer 
patients. We assessed whether aberrant expression of specific microRNAs could 
contribute to brain metastasis. Comparison of primary lung tumors and their matched 
metastatic brain disseminations identified shared patterns of several microRNAs, 
including common down-regulation of miR-145-5p. Down-regulation was attributed 
to methylation of miR-145’s promoter and affiliated elevation of several protein 
targets, such as EGFR, OCT-4, MUC-1, c-MYC and, interestingly, tumor protein D52 
(TPD52). In line with these observations, restored expression of miR-145-5p and 
selective depletion of individual targets markedly reduced in vitro and in vivo cancer 
cell migration. In aggregate, our results attribute to miR-145-5p and its direct targets 
pivotal roles in malignancy progression and in metastasis.
INTRODUCTION
Almost one third of patients with systemic cancers 
develop brain metastases [1, 2]. In fact, brain metastases 
represent the most frequent occurring intracranial 
neoplasm in adult [2] and as such are a major cause of 
morbidity and mortality in patients with systemic cancers. 
The vast majority of brain metastases originate from 
primary carcinoma of either lung (40-50%) or breast 
(20-30%) as well as from melanoma (5-20%) [3, 4]. 
Currently, therapeutic approaches to treat brain metastases 
include surgery, whole-brain radiation therapy (WBRT), 
stereotactic radiosurgery (SRS), targeted-chemotherapy, 
or specific combinations of these treatments [5, 6]. 
Survival of patients with brain metastases typically ranges 
from 4-6 months, but might extend up to 12-24 months. 
This depends on diverse prognostic factors, such as age, 
general conditions, single or multiple brain metastases, co-
occurrence of metastases at other sites, and the status and 
nature of the primary tumor [7]. 
MicroRNAs (miRs) are small non-coding RNAs 
of 18-22 nucleotides, which promote degradation and 
translational inhibition of imperfectly complementary 
target messenger RNAs [8]. MiRs are directly involved 
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in the pathogenesis of many human cancers, including 
leukemia, lung, breast, brain, liver, colon, prostate 
and ovarian cancers [9, 10]. MiRs finely tune several 
cellular processes, including cell growth, apoptosis, 
differentiation, senescence, invasion and migration, and 
therefore might function as either tumor suppressors or 
oncogenes [11]. Altered miR expression leads to aberrant 
modulation of messenger RNAs whose encoded proteins 
can therefore undergo either up-regulation or down-
regulation. Disregulation of miR expression in cancers can 
be ascribed to epigenetic changes, for instance aberrant 
DNA methylation and histone modification, and genetic 
alterations [12]. These can affect the synthesis of primary 
RNAs, miR processing/maturation and/or miR interaction 
with target mRNAs [13]. Many miRs are uniquely and 
differentially expressed in certain cancers compared to 
normal tissues, and miR expression profiles are currently 
considered as robust prognostic markers [9, 10, 14-17]. 
The present study focuses on miR profiles derived 
from brain metastases of human non-small-cell lung cancer 
(NSCLC). By applying our analyses to 29 patients we 
aimed at identifying a recurring signature characterizing 
metastatic brain lesions. Normal brain tissues (N = 6) 
collected from autopsies of patients deceased from causes 
other than lung cancer were used as control samples. In 
addition, to gain specificity we used brain metastases 
of melanoma or breast origin. Another comparator we 
utilized was normal lung tissue, collected from the peri-
tumoral area of matched primary NSCLC lesions. These 
analyses uncovered consistent down-regulation of miR-
145-5p expression in brain metastases, which we found 
to be caused by increased methylation of CpG islands in 
the 5’ regulatory region of miR-145-5p. As a consequence, 
the abundance of OCT-4 and EGFR, two validated targets 
of miR-145-5p, was increased in primary lung cancer and 
their matched-brain metastasis compared to non-tumoral 
tissues. Treatment of lung cancer cells with inhibitors of 
DNA methylation, such as 5-azacytidine and vorinostat, 
restored miR-145-5p levels and concomitantly reduced 
expression of oncoproteins encoded by miR-145-5p target 
mRNAs. Altogether these findings imply that miR-145-
5p down-regulation enables up-regulation of a group of 
target proteins, whose coordinate activity contributes to 
brain metastasis.
RESULTS
Deregulated microRNA expression between 
primary lung cancers and brain metastases
To explore the involvement of miRs in brain we 
collected FFPE (Formalin-Fixed, Paraffin-Embedded) 
samples from patients affected by one of the 3 main 
types of tumors exhibiting the highest incidence of brain 
metastases, namely melanoma, breast and lung cancer. [3, 
4]. In particular, we focused on 13 primary lung cancers 
and their matched brain metastases; for 10 of these 13 
samples we disposed also of the normal lung tissues. In 
addition, we collected 16 unmatched lung-derived brain 
metastases. Our collection also included 6 brain metastases 
from melanoma, 9 brain metastases from breast cancer and 
6 non-tumoral brain tissues derived from autopsy (Table 
1). We profiled the expression of 906 human miRs in 13 
primary lung cancers and their matched brain metastases, 
Table 1: Casuistry description.
FFPE samples
normal brain (autopsy)  * 6
normal lung (matched) 10
primary lung cancer   * 13
brain metastases from lung (matched)   * 13
brain metastases from lung  16
brain metastases from breast 9
brain metastases from melanoma 6
* = samples profiled for microRNAs expression on Agilent platform
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Figure 1: miR-145-5p expression is down-regulated in brain metastases. A. Heat map of the identified signature of 8 miRs 
differentially expressed in 13 brain metastasis (BM) versus 13 matched primary lung cancer (PLC). B. Unsupervised principal component 
analysis (PCA). C. qRT-PCR analysis of miR-145-5p expression levels in 10 normal lung (NL), 13 matched primary lung cancer (PLC), 
and 29 brain metastases from lung (13 matched and 16 unmatched) (BML). D. qRT-PCR analysis of miR-145-5p expression levels in 6 
normal brain (NB), 29 brain metastases from lung (BML) and 15 brain metastases from melanoma (6) and breast (9) (BM). E. Schematic 
representation of miR-145-5p CpG island genomic localization. F.-G. Pyrosequencing analysis of miR-145-5p CpG island methylation 
status in a representative patient of the casuistry (NL= normal lung; PLC= primitive lung cancer; BM= brain metastases; p= patient; reg1= 
region 1; reg2= region 2). 
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and 2 non-tumoral brain tissues. These analyses identified 
8 miRs that were differentially expressed between primary 
lung tumors and brain metastases (Figure 1A and Table 
2). In particular, 6 miRs (miR-219-2-3p, miR-219-5p, 
miR-124, miR-9*, miR-128, miR-338-3p) were up-
regulated, while miR-145-5p and miR-1280 were down-
regulated in brain metastases compared to primary lung 
cancers. Unsupervised principal component analysis 
(PCA) showed that the expression levels of these 8 miRs 
discriminated the group of primary lung cancer samples 
from that of brain metastases (Figure 1B). The significance 
level of the difference between signal distributions of the 
eight selected miRs within the 26 analyzed samples was 
determined with supervised statistical test (Supplementary 
Figure S1A). To further evaluate the reliability of these 
results, we analyzed the expression levels of one up-
regulated miR, miR-219-5p, and one down-regulated 
miR, miR-145-5p, in all 13 matched samples (primary 
lung cancer and matched brain metastases) by qRT-
PCR (Supplementary Figure S1B). These experiments 
confirmed the results obtained by the array analysis.
miR-145-5p expression is down-regulated in brain 
metastasis
We focused our attention on miR-145-5p, a well-
known tumor suppressor miR, the expression of which 
is down-regulated in several tumor types compared to 
the respective normal tissue [18-22]. MiR-145-5p is an 
intergenic miR residing within a cluster that also includes 
miR-143-3p, another well-known tumor suppressor 
miR, as well as the complementary miRs miR-145-3p 
and miR-143-5p (Supplementary Figure S2A). Unlike 
previous analyses that reported similar expression patterns 
of miR-143-3p and miR-145-5p [23-25], we found that 
miR-143-3p expression was not co-regulated as shown 
by analysis of miR arrays (Supplementary Figure S2B). 
Similarly, no co-modulation of miR-143-5p and miR-145-
3p was observed when comparing native tumors to brain 
metastases (Supplementary Figure S2B). Interestingly, 
miR-145-5p down-regulation was even stronger when 
comparing non-tumoral lung tissues and matched primary 
lung tumors (Figure 1C). Furthermore, down-regulation 
appeared to be specific to brain metastases, regardless 
of primary tumors tissue origin. Thus, miR-145-5p 
expression was down-regulated also in brain metastases 
originated from melanoma or from breast tumors when 
compared to normal brain (Figure 1D). Taken together, 
these findings might suggest that down-regulation of miR-
145-5p is common in brain metastases, irrespective from 
the type of the originating primary tumor.
CpG island methylation restrains the expression 
of miR-145-5p
To dissect molecular mechanisms underlying 
the decreased abundance of miR-145-5p in primary 
lung cancers and in brain metastases, we searched for 
potential epigenetic modifications affecting the regulatory 
regions of the miR-145 locus. To this end, we assessed 
Table 2: miRs differentiating brain metastases from primary lung cancer tissues in 13 matched samples of the 
casuistry. Differentiating miRs are listed with their p-values obtainded by paired t-test (pval). In the table are also indicated 
false discovery rate values (FDR), and folds of deregulation expressed in logaritmic scale (log2 fold).
miR pval (Ttest paired) FDR log2 fold
hsa-miR-9* 0.0021 0.08 4.51
hsa-miR-124 0.0023 0.10 5.38
hsa-miR-128 0.0024 0.30 2.41
hsa-miR-145 0.0045 0.09 -1.75
hsa-miR-219-5p 0.0052 0.09 3.43
hsa-miR-338-3p 0.01 0.10 2.81
hsa-miR-219-2-3p 0.01 0.21 1.71
hsa-miR-1280 0.01 0.23 -2.26
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the methylation status of a CpG island located 200 bp 
upstream to the genomic sequence encoding pre-miR-145-
5p (Figure 1E). This was tested in normal lung tissue, the 
primitive lung cancer and brain metastases derived from 
3 representative patients of our cohort. These analyses 
uncovered a significant increase in the methylation status 
of miR-145 CpG island when normal lung tissues were 
compared to primitive lung cancer and brain metastases 
(Figure 1F-1G and Supplementary Figure S3A-B). 
Congruently, methylated-DNA immunoprecipitation 
(meDIP), using an antibody specific to 5’methyl-cytosine 
revealed increased methylation of the analyzed CpG island 
(Supplementary Figure S3C). Altogether these findings 
propose that CpG island methylation within the miR-
145 regulatory region contributes to down-regulation of 
mature miR-145-5p in brain metastases.
To further investigate the impact of methylation on 
the regulation of miR-145-5p expression we assessed the 
effects induced by two chemical epigenetic modifiers, 
namely 5-azacytidine (5-aza-Cd) and vorinostat (SAHA) 
on the abundance of miR-145-5p in 3 different metastatic 
cancer cell lines, namely H1299 (NSCLC), MDA-MB-231 
(breast cancer) and M14-mel (melanoma). We found that 
both 5-aza-Cd and SAHA restored the expression of 
Figure 2: Restoration of miR-145-5p expression restrains in vivo and in vitro tumor invasion. A. Tumor engraftment of 
A549 cells subcutaneously injected in 6-weeks old athymic nu/nu mice. B. Human non-small cell lung carcinoma A549-luc and the A549-
miR145-5p cells were orthotopically injected below the dura. Tumor cell growth was monitored twice a week conducting quantitative 
bioluminescence imaging (qBLI) using the IVIS200 imaging station (Caliper Life Sciences), beginning one week after tumor cell injection. 
C. Numbers of engrafted tumors derived from A549-luc and A549-miR-145-5p cells respectively. D. Bioluminescence images were 
acquired at day 5, 8 and 20 after the orthotopical injectione with the IVIS Spectrum imaging system (PerkinElmer) and quantified by 
measurement of photon flux (photons/s/cm2/steradian) using the Living Image Software package (Perkin Elmer/Caliper Life Sciences). 
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miR-145-5p in all three cell lines (Supplementary Figure 
S4A-B). This effect was reversible as the replenishment of 
the cell cultures with medium lacking SAHA caused down-
regulation of miR-145-5p expression (Supplementary 
Figure S4C). In addition, 5-azacytidine and vorinostat 
induced the expression of pri-miR-145-5p, the miR-145-
5p precursor (Supplementary Figure S4D), implying that 
methylation release of the miR-145-5p regulatory region 
enhanced transcription of downstream sequences. These 
findings paired with a reduction of the methylation status 
of the CpG island of the regulatory region of miR-145-
5p upon treatment with 5-aza-Cd in the analyzed cancer 
cell lines (Supplementary Figure S4E and Supplementary 
Figure S5). Chromatin immunoprecipitation (ChIP) 
experiments revealed that SAHA treatment increased the 
acetylation status of the regulatory region of miR-145-
5p, again supporting the possibility that the induction of 
mature miR-145-5p is due, at least in part, to the release 
of the inhibitory effect of methylation on chromatin 
conformation (Supplementary Figure S4F). Altogether 
these findings indicated that CpG island methylation 
within the miR-145 regulatory region contributes to the 
observed down-regulation of mature miR-145-5p in brain 
metastases. 
Ectopic expression of miR-145-5p restrains brain 
orthotopic tumor engraftment
To test in vivo the antitumoral effects of miR-
145-5p, we subcutaneously injected nu/nu athymic 
mice with either human lung cancer cells, either control 
A549 cells, or A549 cells expressing an exogenous 
miR-145-5p (A549/miR-145-5p). We firstly observed in 
vitro that ectopic expression of miR-145-5p markedly 
reduced migration of A549 cells but had no effect on 
cell proliferation and viability (Supplementary Figure 
S6A-C). We found that the engraftment of A549/miR-
145-5p cells was significantly less efficient than that of 
A549 control lung cancer cells (Figure 2A). To investigate 
the role of miR-145-5p on brain metastasis we performed 
intracranial orthotopically injection of A549-luc/miR-
145-5p and A549-luc/control cells in nu/nu athymic mice. 
Bioluminescence images collected at day 8 and at day 
20 revealed that A549-luc/miR-145-5p engrafted in 3/10 
mice (30%) while A549-luc/control cells in 7/9 (64%) 
mice (Figure 2B-2D). Specifically, on day 5, three miR-
145 mice displayed ROI >=2. On days 8 and 20, these 
three animals had median (range) ROI of 5.85 (5.75-6.15) 
and 23 (19-25) (Figure 2D). In contrast, on day 5, seven 
miR-145 mice had ROI<2. By day 8 or day 20, these 
seven animals had median (range) ROI of 1.32 (1-2.8) 
and 0.8 (0.2-2.6), respectively (Figure 2D). The median 
differences were statistically significant (p = 0.022 at day 
8 and p = 0.017 at day 20). In parallel, amongst control 
mice, on day 5 seven animals had ROI >=2, and on day 
8 and 20 these animals displayed median (range) ROI of 
5.53 (4.3-12.4) and 13.8 (10-32) (Figure 2D), respectively. 
On day 5, the two control mice displayed ROI<2 and their 
median (range) on day 8 and day 20 were ROI of 1.55 
(0.9-2.2) and 1.15 (1-1.3), respectively (Figure 2D). The 
median differences were statistically significant (p = 0.056 
at day 8 and day 20). Altogether these findings strongly 
support an in vivo evidence of the role of miR-145-5p in 
brain metastasis.
Ectopic expression of miR-145-5p impairs cell 
migration
It has been previously reported that miR-145-
5p exerts anti-tumoral effects ranging from growth 
arrest to inhibition of cell invasion [18, 26-29]. These 
effects are cell context dependent and occur through 
the selective targeting of specific mRNAs [30-33]. We 
found that ectopic expression of miR-145-5p markedly 
reduced migration of H1299 cells (Figure 3A-3B and 
Supplementary Figure S7A-B). On the contrary, miR-
Table 3: miR-145-5p characterized targets with the relative references.
gene target reference
c-myc Sachdeva et al., 2009Breast cancer cells
EGFR Cho WC et al., 2011Lung cancer cells
MUC1 Sachdeva M and  Mo Y Y, 2010Breast cancer cells
Oct4 Yin   et al., 2011Lung cancer cells
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145-5p depletion determined an increase in cell migration 
(Supplementary Figure S7C). Interestingly, SAHA 
treatment of H1299 cells, which in part acts through 
the induction of miR-145-5p, impaired cell migration 
to a similar extent than that provoked by miR-145-5p 
ectopic expression (Figure 3C). No effects of miR-145-
5p ectopic expression on H1299 cell proliferation were 
evidenced (Supplementary Figure S7D). Similar findings 
were observed upon ectopic expression of miR-145-5p or 
treatment of MDA-MB-231 cells with SAHA (Figure 3D-
3E).
Down-regulation of miR-145-5p releases the 
expression of OCT4, EGFR, MUC-1 and c-MYC 
proteins
Loss of tumor suppressor miRs is a frequent 
alteration in human tumors and leads to the heightened 
expression of proteins encoded by their target mRNAs. 
Indeed, we found that the expression of OCT-4 protein 
whose mRNA is a known target of miR-145-5p, was 
increased in both primary lung cancers and matched 
brain metastases when compared to matched normal lung 
tissues (Figure 3F-3G and Supplementary Figure S8) [30]. 
Ectopic expression of miR-145-5p in H1299 cells reduced 
OCT-4 protein expression (Figure 3H). This occurred 
through the direct binding of miR-145-5p to the 3’UTR 
of OCT-4 mRNA (Figure 3I). SAHA treatment, that 
induced miR-145-5p expression, reduced OCT-4 protein 
levels (Figure 3L). Interestingly, siRNA-mediated knock 
down of OCT-4 protein expression markedly reduced the 
migration of H1299 cells (Figure 3M). 
Similar to OCT-4 protein, the expression of 
EGFR was increased (Figure 4A) in the same set of 
tissues analysed in Figure 3F (Figure 4A-4B). Ectopic 
expression of miR-145-5p reduced the expression of 
EGFR, while its depletion determined an increase EGFR 
in protein levels, and this occurred through the direct 
binding to the 3’UTR of EGFR mRNA (Figure 4C-4D 
and Supplementary Figure S10B) [31]. SAHA treatment 
reduced EGFR expression both the transcript and the 
protein levels (Figure 4E-4F). It has been shown that 
EGFR nuclear localization is enhanced by EGFR binding 
to MUC-1, with reduced expression of MUC-1 causing 
depletion of nuclear EGFR [34]. Since MUC-1 has been 
reported to be a target of miR-145-5p we aimed to assess 
whether its ectopic expression reduced MUC-1 protein 
level and impaired EGFR nuclear localization [32]. We 
found that ectopic expression of miR-145-5p markedly 
reduced MUC-1 expression (Figure 5A). Interestingly, 
this paired with marked reduction of EGFR nuclear 
localization, its tyrosine phosphorylation at residue 1068 
and the induction of its downstream target MET (Figure 
4G-4I and Supplementary Figure S9A). siRNA-mediated 
depletion of MUC-1 expression impaired EGFR nuclear 
localization (Figure 4L and Supplementary Figure S9B) 
[34]. Ectopic expression of miR-145-5p reduced the 
expression of two downstream effectors of MUC-1, such 
as β-catenin and Cyclin D1 (Supplementary Figure S10A). 
SAHA treatment reduced the expression of MUC-1 
protein (Figure 5B). Similarly to SAHA treatment, siRNA-
mediated knock down of MUC-1 expression impaired 
migration of H1299 cells (Figure 5C). 
It has been previously shown that c-MYC is a target 
of miR-145-5p [33]. We found that ectopic expression 
of miR-145-5p reduced the expression of MYC protein 
while its depletion determined an increase in protein 
levels (Figure 5D and Supplementary Figure S10B). This 
occurred through the direct binding of either ectopically 
expressed or SAHA-induced expression of miR-145-5p 
to the 3’UTR of MYC mRNA (Supplementary Figure 
S10C-D). SAHA treatment reduced the expression of 
both MYC transcript and protein as a consequence of 
restoration of miR-145-5p expression (Figure 5E-5F). 
Depletion of c-MYC expression impaired migration of 
H1299 cells (Figure 5G).
Altogether these findings imply that miR-145-5p 
down-regulation releases aberrant expression of pro-
invasive factors such as OCT-4, c-MYC, MUC-1 and 
instigates, directly as well as indirectly (i.e. via MUC-1) 
aberrant EGFR signaling (Table 3).
Tumor protein D52 (TPD52) is a novel target of 
miR-145-5p
To further dissect the contribution of miR-145-5p 
down-regulation to metastasis we searched for additional, 
yet undiscovered, mRNA targets, the annotated functions 
of which could be related to dissemination of tumor cells. 
Putative mRNA targets of miR-145-5p were identified 
using miRWalk [35]. Next, permutation tests and false 
discovery procedures were used to further select out 
of the shortlisted miRs several mRNA targets that are 
deregulated when normal and tumoral samples are 
compared in The Cancer Genome Atlas (TCGA) lung 
adenocarcinoma data set (Figure 6A) [36]. Among these 
mRNAs, we noted TPD52, whose product promotes 
metastasis. Thus, TPD52 emerged as a potential and 
biologically relevant target of miR-145-5p in the process 
of metastatic colonization of brain [37, 38]. As shown in 
Figure 6B and Supplementary Figure S11A, TPD52 gene 
expression was found to be inversely correlated to miR-
145-5p expression in both lung and breast cancer data sets 
from the TCGA consortium [36, 39]. Moreover in the lung 
data set we observed strong down-regulation of miR-145-
5p and up-regulation of TPD52 mRNA when comparing 
tumoral and matched normal samples (Figure 6C). 
Indeed, the 3’-UTR of TPD52 contains two consensus 
binding sites miR-145-5p (Supplementary Figure S11B). 
Interestingly, TPD52 protein expression was increased in 
Oncotarget35190www.impactjournals.com/oncotarget
Figure 3: miR-145-5p expression impairs cell migration of H1299 and MDA-231 cells and inhibits Oct-4 protein. A. 
Wound healing assay in H1299 cells upon miR-145-5p over-expression. B.-E. Transwell migration assay in H1299 and MDA-231 cells 
upon miR-145-5p over-expression B. and D. or 24 hours of 5 uM vorinostat (SAHA) treatment C. and E. F. Immunohistochemistry for 
Oct-4 in 2 representative patients slides (pt=patient). G. Percentage of positive Oct-4 staining in tissues (PLC= primary lung cancer; BM= 
brain metastases). H. Oct-4 immunocitochemistry in H1299 cells upon miR-145-5p over-expression. I. Renilla luciferase activity of Oct-4-
3’UTR reporter gene in H1299 transiently transfected with miR-145-5p mimic or control mimic. L. Oct-4 immunocitochemistry in H1299 
cells upon 24 hours of 5 uM vorinostat (SAHA) treatment. M. Transwell migration assay in H1299 cells upon Oct-4 RNA interference.
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Figure 4: miR-145-5p impairs the expression of EGFR protein. A. Immunohistochemistry for EGFR in 2 representative patients 
slides (pt=patient). B. Quantification of positive EGFR staining in tissues. C. Western-blot analysis of EGFR protein expression in H1299 
cells upon miR-145-5p over-expression. D. Renilla luciferase activity of EGFR-3’UTR reporter gene in H1299 transiently transfected with 
miR-145-5p mimic or control mimic. E. qRT-PCR analysis of EGFR mRNA levels in H1299 cells upon 5 uM vorinostat (SAHA) treatment. 
F. Western-blot analysis of EGFR in H1299, MDA-231 and M14 cells upon 24 hours of vorinostat (SAHA) treatments. G. Quantification of 
immunofluorescence assay to analyze EGFR localization in H1299 cells treated with EGF (20 ng/mL) upon miR-145-5p over-expression. 
H. Analysis of pEGFR protein expression levels in H1299 cells treated with EGF (20 ng/mL) or maintained in serum free (Sf) medium 
upon miR-145-5p over-expression. I. c-Met protein levels in H1299 cells treated with EGF (20 ng/mL) or maintained in serum free (Sf) 
medium upon miR-145-5p over-expression. L. Quantification of immunofluorescence assay to analyze EGFR localization in H1299 cells 
treated with EGF (20 ng/mL) upon MUC-1 RNA interference.
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Figure 5: miR-145-5p impairs the expression of MUC-1 and MYC proteins. A. MUC-1 immunocitochemistry in H1299 cells 
upon miR-145-5p over-expression. B. MUC-1 immunocitochemistry in H1299 cells upon 5 uM vorinostat (SAHA) treatment. C. MUC-1 
immunocitochemistry in H1299 cells upon MUC-1 RNA interference (left panel) and transwell migration assay in the same conditions 
(right panel). D. Western-blot analysis of MYC protein expression levels in H1299 cells upon miR-145-5p over-expression. E. qRT-PCR 
analysis of MYC mRNA levels in H1299 cells upon 24 hours of 5 uM vorinostat (SAHA) treatment. F. Western-blot analysis of MYC in 
H1299, MDA-231 and M14 cells upon 24 hours of vorinostat (SAHA) treatments. G. MYC protein levels in H1299 cells upon MYC RNA 
interference and transwell migration assay in the same conditions.
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Figure 6: miR-145-5p impairs the expression of TPD52 protein. A. List of the most significant miR-145-5p putative target 
genes with a known role in metastasis pathways, that resulted to be inversely correlated to miR-145-5p expression in the TCGA casuistry 
of 526 lung adenocarcinoma tissues. Genes were ranked by the number of the softwares that predicted miR-145-5p binding on the 3’UTR. 
B. Heat map of TPD52 and miR-145-5p genes expression in 526 tumoral samples of lung adenocarcinoma TCGA casuistry. C. miR-145-
5p and TPD52 genes expression in matched samples of normal (N) and tumoral (T) tissues of lung adenocarcinoma TCGA casuistry. D. 
Immunohistochemistry for TPD52 in 2 representative patients slides (pt=patient). E. Western-blot analysis of TPD52 protein expression 
in H1299 cells upon miR-145-5p and miR-145-3p mimics over-expression. F. qRT-PCR analysis of TPD52 mRNA levels in H1299 cells 
upon 24 hours of 5 uM vorinostat (SAHA) treatment. G. Western-blot analysis of TPD52 in H1299 upon vorinostat (SAHA) treatments. 
H. TPD52 protein levels in H1299 cells upon TPD52 RNA interference (left panel) and transwell migration assay in the same conditions 
(right panel).
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matched brain metastasis, when compared to both normal 
lung and primary lung cancer tissues (Figure 6D). In line 
with these observations, ectopic expression of miR-145-
5p reduced the TPD52 protein levels (Figure 6E). This 
effect was not evidenced upon expression of miR-145-3p 
that is produced by the complementary strand of the miR-
145 locus (Figure 6E). Interestingly, treatment of H1299 
cells with vorinostat, which restored the expression of 
miR-145-5p, led to a reduction of TPD52 transcript and 
protein levels (Figure 6F-6G). At the functional level, 
siRNA-mediated knock down of TPD52 (siTPD52_1) 
markedly impaired migration of H1299 cells (Figure 6H), 
but siTPD52_2 or siGFP oligonucleotides, which failed 
to affect TPD52 expression, did not have any effect on 
migration of H1299 cells (Figure 6H).
Altogether, these findings identify TPD52 as a 
novel target of miR-145-5p. This implies that the aberrant 
expression of TPD52 due to loss of miR-145-5p activity 
might contribute to the metastatic process.
DISCUSSION
This study identified a miR signature unique to brain 
metastases that originated in lung primary tumors. Previous 
work provided evidence supporting the ability of distinct 
miR signatures to differentiate between non-tumoral and 
tumoral tissues, as well as characterize specific subtype 
of disease [15-17, 20]. Adopting the newly identified miR 
signature, our study later focused on the miR-145 locus. 
This was motivated by previous reports that implicated 
the miR-145 locus in tumor suppression [18, 20, 26-29]. 
Unlike previous findings, which reported co-modulation of 
both chromosome 5 encoded miR-145 and miR-143, we 
found that expression of only miR-145-5p, but not miR-
145-3p, miR-143-5p and miR-143-3p, was significantly 
different when comparing primary NSCLC lesions to their 
brain metastases. Down-regulation of both miR-145-3p 
and miR-145-5p has recently been reported as a long-term 
predictor of breast cancer using a case control-study nested 
in the ORDET prospective cohort study [19]. MiR-145-
5p down-regulation was also reported in bone metastasis 
derived from primary prostate cancers [40]. MiR-145-5p 
Figure 7: Schematic representation of the proposed molecular mechanism. In highly metastatic lung cancer cells miR-145-5p 
expression is maintained at low levels by epigenetic modifications, such as hypermetylation and deacetylation of its promoter. Treatments 
with epigenetic drugs, such as vorinostat (SAHA) and 5-azacytidine (5-aza), could restore miR-145-5p expression, that in turns has a strong 
inhibitory effect on OCT-4, EGFR, MUC-1, MYC and TPD52 proteins expression. In particular MUC1 protein down-regulation potentiates 
the inhibitory effect on EGFR activity as it prevents EGFR nuclear localization. The final effect of miR-145-5p multi-targeting activity 
restoration results in a significant inhibition of the migratory ability of lung cancer.
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down-regulation was also present, but significantly less 
pronounced, when comparing primary non-small lung 
cancers with matched non-cancerous lung tissues. In light 
of the results reported by Muti and colleagues it is likely 
that miR-145-5p down-regulation occurs early during 
tumorigenesis and it confers high metastatic potential. 
In this context, it is worthwhile mentioning that down-
regulation of 24 miRs preceded and instigated massive up-
regulation of oncogenic mRNAs in breast cancer cell lines, 
upon EGF stimulation. Collective down-regulation of this 
panel of miRs was also found when breast non-tumoral 
tissues were compared to matched tumoral tissues [41]. 
Along this vein, we found that miR-145-5p suppresses 
known target mRNAs, such as those encoding the potent 
oncoproteins OCT-4, EGFR, c-MYC, MUC-1 as well as 
the newly identified target TPD52. Accordingly, these 
mRNAs and proteins were up-regulated in both primary 
lung cancers and derived brain metastases, relative to 
non-tumoral lung tissues. Intriguingly, we previously 
showed that while miR-145-3p over-expression reduced 
proliferation of breast cancer cells, restoration of miR-
145-5p activity impaired migration of breast cancer cell 
lines [19]. Indeed, we found that ectopic expression of 
miR-145-5p inhibited migration of lung adenocarcinoma 
cell lines without reducing cell proliferation. Similarly to 
the effect of miR-145-5p, selective knockdown of OCT-
4, EGFR, MYC, MUC-1 and the newly identified TPD52 
impaired migration of lung cancer cells. Currently, we 
poorly understand how miRs impact their target transcripts 
in a spatial and temporal specific manner in cancer. The 
mechanism might depend upon many factors, including 
cell context, affinity for and number of binding sites within 
the 3’UTRs of the target mRNAs, threshold of either up- 
or down-regulation of a specific miR, number of miRs that 
can simultaneously target a specific mRNA, miR location 
(intra- or intergenic) and the peculiarity of their respective 
genomic regulatory regions. Some of theses parameters 
might be more relevant than others when it comes to the 
regulation of a set of 5 important oncoproteins by miR-
145-5p.
Epigenetic alterations on the regulatory region can 
also lead to aberrant expression of a specific miR [12]. 
Interestingly, we found that CpG island methylation at the 
miR-145 locus occurred in both primary lung cancers and, 
to a more pronounced extent, in matched brain metastases 
when compared to non-tumoral lung tissues. Restoration 
of miR-145-5p expression using either vorinostat or 
5-azacytidine, which released methylation of the miR-145 
locus, led to inhibition of migration of lung cancer cells 
and to down-regulation of OCT-4, MYC, EGFR, MUC-
1 and TPD52 expression. Thus, it appears that selective 
down-regulation of miR-145-5p due to methylation of its 
regulatory regions might contribute, at least partially, to the 
establishment of a network of oncogenic proteins leading 
to metastasis. Strikingly, each of the verified miR-145-5p 
targets has been shown to play critical roles in migration, 
invasion and resistance to radio- and chemotherapy of 
advanced tumors [38, 42-45]. These features are shared 
by brain metastases, which are currently considered a 
major clinical issue in patients with advanced lung, breast, 
melanoma and renal cell cancer. Initial treatment of brain 
metastases typically includes radiotherapy, either whole 
brain radiotherapy (WBRT), stereotactic radiosurgery 
(SRS), or both. Surgical resection is generally reserved 
for good prognosis patients with limited extracranial 
metastases and a single brain lesion. For patients 
progressing through the up-front treatment, the therapeutic 
approach is quite variable and there are no standardised 
protocols. Targeted therapies, such as lapatinib, erlotinib, 
gefitininb and B-RAF inhibitors are increasingly used 
for the treatment of brain metastases from diverse solid 
tumors. A combined epigenetic therapy with 5-azacytidine 
and entinostat, inhibitors of DNA methylation and histone 
deacetylation, respectively, within a phase I/II trial in 
patients with recurrent metastatic NSCLC was well-
tolerated and objective responses were observed [46]. 
Demethylation of four genes (APC, RASSF1a, CDH13, 
and CDKN2a) with negative prognostic impact on non-
small lung cancer was observed in free plasma DNA of 
the 19 enrolled patients [46]. Altogether, these findings 
along the miRNA/mRNAs (miR-145-5p/EGFR-cMYC-
MUC1-OCT4-TPD52) network here documented raise 
the possibility of, combining epigenetic drugs with 
conventional chemotherapy and oncogene-targeted 
therapeutics might hold great promises for rational-based 
therapeutic management of metastatic tumors.
MATERIALS AND METHODS
Cell cultures and treatments
Human cell lines H1299 and A549 were grown 
in RPMI medium (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% FBS, MDA-MB-231 cells 
and M14-mel cells were cultured in DMEM medium 
(Invitrogen-GIBCO,Carlsbad, CA, USA) with 10% (v/v) 
FBS; all cell lines were grown at 37 °C in a balanced air 
humidified incubator with 5% CO2.
Cells were treated at the indicated concentration with 
vorinostat (SAHA), a histone deacetylase inhibitor, and 
with 5-azacytidine (5-aza-cd), a DNA methyltransferase 
inhibitor. MDA-MB-231 and M14-mel cells were 
harvested in colture for 96 hours and treated with 5-aza-cd 
after 24 hours and 72 hours. H1299 cells were maintained 
in colture for 96 hours and treated with 5-aza-cd every 24 
hours for 3 days and with fresh medium without 5-aza-
cd for the last 24 hours. For SAHA treatment, cells were 
plated and treated at the indicated concentration for 24h 
after which cells were harvested.
To analyse EGFR localization, H1299 cells 
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were transfected with Pre-miRNA Precursor-Negative 
Control (Ambion) and Pre-miRNA145 (Ambion) at 
final concentration of 5nM and 48h after transfection the 
medium was replaced with RPMI without FBS. After 24h 
cells were treated with EGF (Sigma) at 20 ng/ml for 6h.
For evaluation of c-Met expression levels, H1299 
cells were transfected with Pre-miRNA Precursor-
Negative Control (Ambion) and Pre-miRNA145 (Ambion) 
at final concentration of 5nM and 48h after transfection the 
medium was replaced with RPMI without FBS. After 24h 
cells were treated with EGF (Sigma) at 20 ng/ml and 48h 
after treatment cells were harvested.
Plasmids and transfections
For mature miR-145-5p expression, we used Pre-
miRNA Precursor-Negative Control (Ambion) and Pre-
miRNA145-5p (Ambion) at final concentration of 5nM. 
For miR-145-5p depletion we used Anti-miR miRNA 
Inhibitor Negative Control (Ambion) and Anti-miR 
has-miR-145-5p miRNA Inhibitor (Ambion) at final 
concentration of 10nM. H1299, MDA-MB-231 and 
M14-mel cells were transfected using Lipofectamine 
RNAiMAX (Invitrogen) according to the manufacturer’s 
instructions.
For Luciferase assay H1299 cells were co-
transfected in 24-well dishes using Lipofectamine 2000 
(Invitrogen) with 200ng of OCT4-3’-UTR-(wt and 
mutant)-Luciferase vectors (a kind gift of Dr. Kenneth 
Kosik, UCSF Santa Barbara, CA, United States), 20 
ng of the transfection control Renilla vector (phRLTK, 
Promega), and the pre-miRNA Precursor-Negative 
Control (Ambion) or the Pre-miRNA145-5p (Ambion) at 
the indicated concentrations. 
Moreover H1299 cells were transfected in 24-well 
dishes using Lipofectamine 2000 (Invitrogen) with 25 ng 
of psiCHECK-2 reporter vector containing the 3’-UTR 
of the putative target gene Myc together with the pre-
miRNA Precursor-Negative Control (Ambion) or the Pre-
miRNA145 (Ambion) at the indicated concentration. Cells 
were harvested 48 hours post transfection and luciferase 
activities were analyzed by the dual-luciferase reporter 
assay system (Promega, Madison, WI) in the GloMax 96 
Microplate Luminometer (Promega). Firefly luciferase 
was used to normalize the Renilla luciferase.
In addition H1299 cells were treated with 1 and 2,5 
uM of SAHA for 24h to induce miR-145-5p expression 
and luciferase activity was tested as previously described.
For siRNA experiments, H1299 were transfected 
with siGFP (5’-AAGUUCAGCGUGUCCGGGGAG-3’), 
as control and siMYC 
(5’-GCCACAGCAUACAUCCUGU-3’) at 400 pmoli, 
siOCT4 (AAGGAUGUGGUCCGAGUGUGG), 
siMUC1 (5’-AAGACUGAUGCCAGUAGCACU-3’), 
siTPD52_1(GCGGAAACUUGGAAUCAAU) and 
siTPD52_2 (GGAGAAGUCUUGAAUUCGG) at 600 
pmoli (Eurofins, MWG, Operon) for 48 hours.
Study population
The cohort of paraffin-embedded tissues (FFPE) 
used for array validation consisted of 13 serial matched 
samples, primary lung cancers (PLC) and brain metastases 
(BML) plus 16 brain metastases from lung cancer (BML) 
and 2 normal brains (NB). Four additional cases of 
normal brain (NB), 6 brain metastases from melanoma 
and 9 brain metastases from breast cancer (BM) were 
recruited for qRT-PCR analysis of miR-145 expression 
levels. Following excision, fresh tissue samples were 
immediately frozen in liquid nitrogen and stored at -80°C 
until RNA extraction. All tissue samples used throughout 
the study were obtained from patients from Italian 
National Cancer Institute ‘Regina Elena’, Rome, Italy. The 
ethical committee of the institute has approved the study.
RNA extraction, labeling and microarray 
hybridization
RNA from FFPE samples was extracted using 
the miRneasy FFPE kit (QIAGEN) following the 
manufacturer’s instructions. The concentration and 
purity of total RNA were assessed using a Nanodrop 
TM 1000 spectrophotometer (Nanodrop Technologies, 
Wilmington, DE, USA). Total RNA (100 ng) was labeled 
and hybridized to Human miRNA Microarray Rel 14 V2 
(Agilent). Scanning and image analysis were performed 
using the Agilent DNA Microarray Scanner (P/N 
G2565BA) equipped with extended dynamic range (XDR) 
software according to the Agilent miRNA Microarray 
System with miRNA Complete Labeling and Hyb Kit 
Protocol manual. Feature Extraction Software (Version 
10.5) was used for data extraction from raw microarray 
image files using the miRNA_105_Dec08 FE protocol.
Total RNA extraction from cells and reverse 
transcriptase
Total RNA was extracted using the TRIZOL 
Reagents (GIBCO). One microgram of total RNA 
was reverse-transcribed at 37°C for 60 minute in the 
presence of random hexamers and Moloney murine 
leukemia virus reverse transcriptase (Invitrogen). Specific 
oligonucleotides for the genes listed in Supplementary 
Table 1 and Supplementary Table were used for PCR 
analyses. GAPDH, TPD52, MYC and EGFR genes 
expressions were measured by real-time PCR using the 
Sybr Green assay (Applied Biosystems, Carlsbad, CA, 
USA) on a StepOne instrument (Applied Biosystems).
Small amount of RNA (10 ng) was reverse-
transcribed using the TaqMan microRNA Reverse 
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Transcription Kit (Applied Biosystem) and Real time-PCR 
of miR expression was carried out in a final volume of 
10 ul using ABI Prism 7000 Sequence Detection System 
(Applied Biosystems). The PCR Reactions were initiated 
with a 10 minute incubation at 95°C followed by 40 cycles 
of 95°C for 15 seconds and 60°C for 60 seconds. RTq-
PCR quantification of miR expression was performed 
using TaqMan MicroRNA® Assays (Applied Biosystems) 
according to the manufacturer’s protocol. RNU19 was 
used as endogenous control to normalize miR expression. 
All reactions were performed in duplicate. 
For measurement of the precursor miR expression, 
PCR was performed using 2X red Mix DNA Polymerase 
MasterMix (RBC Bioscence) using the primers listed in 
Supplementary Table 1.PCR was performed at 95°C for 
5 min, 35 cycles at 95°C for 30 s, 60°C for 40 s and 72°C 
for 40 s followed by a final extension at 72°C for 10 min. 
The PCR products were loaded on 2 % agarose gel for 
analysis.
Lysate preparation and immunoblotting analysis
Cells were lysed in buffer with 50 mM Tris-HCl 
pH 8, with 1% NP-40 (Igepal AC-630) 150mM NaCl, 
5mM EDTA and fresh protease inhibitors. Extracts were 
sonicated for 10 s and centrifuged at 12000 ×rpm for 10 
min to remove cell debris. Protein concentrations were 
determined by colorimetric assay (Bio-Rad).
Western blotting was performed using the following 
primary antibodies: mouse monoclonal anti-Gapdh 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
mouse monoclonal anti-Cyclin D1 (Invitrogen), mouse 
monoclonal anti-Oct4 C-10 (Santa Cruz Biotechnology 
sc-5279), rabbit monoclonal anti-Egfr (Cell Signaling 
Tecnology, C74B9), rabbit polyclonal anti Phospho-Egfr 
(Tyr1068) (Santa Cruz Biotechnology), mouse monoclonal 
anti-Met (25H2) (Santa Cruz Biotechnology), hamster 
monoclonal anti-Muc1 (Ab-5) (Thermoscientific), rabbit 
monoclonal anti-c-Myc ( Cell Signaling D84C12- XP), 
mouse monoclonal anti B-actin (ACTBD11B7) (Santa 
Cruz Biotechnology sc-81178), rabbit polyclonal anti-
TPD52 H-54 (Santa Cruz Biotechnology sc-67063).
Secondary antibodies used were goat anti-mouse, 
goat anti-rabbit, conjugated to horseradish peroxidase 
(Amersham Biosciences,Piscataway, NJ, USA) and 
goat anti-Armenian hamster conjugated to horseradish 
peroxidase (Santa Cruz Biotechnology sc-2443). 
Immunostained bands were detected by chemiluminescent 
method (Pierce, Rockford, IL, USA).
Cell cycle analysis
Samples were collected over the indicated time 
points and fixed in 70% ethanol overnight. Fixed cells 
were treated with RNase for 20 min before addition of 5 
mg/ml PI and analyzed by FACS.
Wound healing assay
H1299 cell lines transfected with pre-miRNA 
Precursor-Negative Control (Ambion) and the Pre-
miRNA145-5p (Ambion), were grown to 80% confluence 
in 6-well tissue culture plates and wounded with a sterile 
200 ul pipet tip to remove cells by perpendicular linear 
scrapes. PBS 1x washing was used to remove loosely 
attached cells. The cells were incubated in full medium 
with 10% FBS for 24 h. The progression of migration 
was photographed immediately, at 16 and at 24 h after 
wounding.
Transwell migration assay
Migration assay was performed using a 24-well 
plate with a non-coated 8-mm pore size filter in the insert 
chamber (BD Falcon, Franklin Lakes, NJ, USA). Cells 
were transfected with pre-miRNA Precursor-Negative 
Control (Ambion) and the Pre-miRNA145 (Ambion), 
or with Anti-miR miRNA Inhibitor Negative Control 
(Ambion) and Anti-miR has-miR-145-5p miRNA Inhibitor 
(Ambion), or treated with SAHA at 0-5 uM, or silenced 
with siMyc at 400 pmoli or siOct4, siMuc1, siTPD52_1 
and siTPD52_2 at 600 pmoli (Eurofins, MWG, Operon). 
After 48 hours from transfection or treatment, cells were 
resuspended in DMEM or RPMI media without FBS 
and seeded into the insert chamber. Cells were allowed 
to migrate for 12 h into the bottom chamber containing 
0,7 ml DMEM or RPMI media containing 5% FBS in 
a humidified incubator at 37°C in 5% CO2. Migrated 
cells which had attached to the outside of the filter were 
visualized by staining with DAPI and counted. 
Immunofluorescence and immunocytochemistry
For immunocytochemistry assay cells were seeded 
onto glass coverslips (Marienfeld laboratory glassware, 
Lauda-Ko¨nigshofen, Germany) at 4x104 cells/well 
into 6-well dishes (COSTAR), transfected with Pre-
miRNA Precursor-Negative Control (Ambion) and 
Pre-miRNA145-5p (Ambion) at final concentration of 
5nM or silenced for the target protein and fixed 48 h 
later with 4% formaldehyde in PBS for 15 min at room 
temperature (RT). Cells were permeabilized with 1% 
Triton X-100 in PBS for 10 min. After washing with PBS, 
the coverslips were incubated with Oct-4 antibody C-10 
(Santa Cruz Biotechnologysc-5279) and Muc1 antibody 
(Ab-5) (Thermoscientific) diluted in 5% BSA/PBS for 1 
h at RT. Cells were incubated with peroxidase inhibitor 
before primary antibody incubation. Protein staining was 
revealed through DAB enzymatic reaction while nuclei 
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were counterstained with hematoxylin.
For immunofluorescence assay, 48h after 
transfection the media was replaced with RPMI without 
FBS. The day after cells were treated with Egf (Sigma) at 
20 ng/ml for 6h and fixed with 4% formaldehyde in PBS. 
Then cells were washed twice with 0.02% Tween-20 and 
1% BSA in PBS, followed by incubation with Alexa Flour 
488 (rabbit) conjugated secondary antibodies (Molecular 
Probes Inc., Eugene, OR, USA) for 30 min at RT. After 
washing three times with 0.02% Tween-20 and 1% BSA in 
PBS, the coverslips were counterstained with DAPI 5 min 
and mounted with Vectashield (Vector Labs,Burlingame, 
CA, USA). Cells were examined under a Zeiss LSM 510 
laser scanning fluorescence confocal microscope (Zeiss, 
Wetzlar, Germany). 
Immunohystochemistry
Formalin-fixed and paraffin-embedded 5 μm sections 
were stained with haematoxylin and eosin or stained with 
anti-Oct-4 antibody (SC-5279, Santa Cruz Biotechnology, 
1:50), anti-EGFR antibody (Cell Signaling Tecnology, 
C74B9, 1:50), anti-TPD52 H-54 (SC-67063, Santa Cruz 
Biotechnology, 1:100) using BENCHMARK ULTRA 
VENTANA (Roche, Tucson, AZ, USA). Seven randomly 
chosen fields from each sample were scored.
Methylated DNA immunoprecipitation assay 
(MeDIP)
Genomic DNA of one patient was isolated using 
the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, 
Germany) and the resulting DNA was quantified on 
a Nanodrop spectrophotometer. Immunoprecipitation 
of methylated DNA was prepared as Weber et al, 
2005; the antibody against 5-methyl-cytosine used for 
immunoprecipitation was from Abcam ab1884, San 
Diego, CA. 
qRT-PCR reactions were carried out in duplicate 
on specific genomic regions using TaqMan Master 
Mix (Applied Biosystem). The list of primers used for 
amplification on methylated region is summarized in 
Supplementary Table 3 . The resulting signals were 
normalized for primer efficiency by carrying out qRT-PCR 
for each primer pair using Input DNA.
DNA isolation, sodium bisulfite conversion and 
pyrosequencing analysis
Genomic DNA was isolated using the QIAamp DNA 
FFPE Tissue Kit (Qiagen, Hilden, Germany). Sodium 
bisulfite modification of 800 ng DNA was performed using 
the DNA Methylation kit (Diatech Pharmacogenetics) 
according to the manufacturer’s protocol. Modified 
DNA was subjected to PCR amplification of the specific 
promoter region of pri-miR-145 using the Corbett Life 
Science Rotor-Gene™ 6000. The primer sequences are 
listed in Supplementary Table 4 . The resulting PCR 
products were analyzed by gel electrophoresis to confirm 
the size of the product and rule out the formation of primer 
dimers. The specific PCR products were then subjected 
to quantitative pyrosequencing analysis using a PyroMark 
Q96 ID (Qiagen) according to the manufacturer’s protocol. 
The genomic location of the bisulfite pyrosequencing 
assays and the number of CpG sites investigated in each 
assay are shown in Figure 1. The pyrosequencing analysis 
was performed with PyroMarker CpG software 1.0.11 
(Qiagen).
Formaldehyde cross-linking and chromatin 
immunoprecipitation
H1299, MDA-MB-231 and M14-mel cells were 
treated with SAHA at the indicated concentration. 
After 24h formaldehyde cross-linking and chromatin 
immunoprecipitations were performed as described 
(Di Agostino et al., 2006). The chromatin was 
immunoprecipitated with anti-acetyl-Histone H4 
antibody (Millipore) or no antibody as negative control. 
Primers used for the amplification by qRT-PCR of the 
different regulatory regions of miR-145-5p are listed in 
Supplementary Table 5. 
Cell proliferation assay
A549 cells were seeded into six-well dishes and 
transfected in triplicated as indicated. 6x104 cells were 
seeded for this assay. Cells were collected and manual 
counted at 0, 24, 48, 72 hours after transfection. 
Viability assay
Cell viability was evaluated using the ATPlite™ 
Luminescence Assay System and following the 
manufacturer’s instructions. Luminescence was read 
by the EnSpire® Multimode Plate Reader (PerkinElmer, 
Whaltman, MA, USA). 
In vivo A549 cells subcutaneous tumor 
engraftment
All studies have been performed in accordance with 
“Directive 86/609/EEC on the protection of animals used 
for experimental and other specific purposes” and made 
effective in Italy by the legislative Decree DL 116/92.
14 athymic nu/nu mice 6-weeks old (Harlan) were 
utilized. After 1 week of acclimation they were housed 
four to a plastic cage and fed on basal diet (4RF24, 
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Mucedola S.r.l.) with water ad libitum, in an animal 
facility controlled at a temperature of 23 ± 2°C, 60 ± 5% 
humidity, and with a 12 h light and dark cycle. Before 
injection, cells were washed once in PBS and then the 
pellet was re-suspended in 50% RGF matrigel (BD 
Biosciences) solution in Medium 199 and injected in the 
right flank of the mice in 200µl volume/mouse. 2x106 
A549 cells/mouse were injected for a total of 7 mice/
group. Tumor growth was monitored weekly by caliper 
measurement and tumor volume was determined by the 
formula (D x d2)/2.
Establishment of orthotopic brain tumor 
xenografts in mice
Human non small cell lung carcinoma A549-luc 
and the A549-miR-145-5p cell lines were collected by 
trypsinization, washed in PBS 1X, centrifuged at 1200 
rpm x 10 mins at RT, re-suspended in PBS 1X w/o Ca++/
Mg++ at the density of 2x105 cells/10 μl (2x107 cell/ml) and 
maintained on ice until the in vivo injection. Stereotaxic 
(Stoelting stereotaxic apparatus) tumor cell injection was 
performed in 20 Athymic nude mice 6 week-old (Harlan). 
Under deep anaesthesia (Zoletil/Rompum, 80 mg/kg +10 
mg/kg) a 2 mm hole was drilled in the skull at the level 
of bregma and the cells suspension was injected into 
mouse brain using a glass micropipette equipped with 26 
gauge needle. Cells were injected setting the stereotaxic 
coordinates to 5 mm below the dura. The solution was 
slowly injected over 4 min and the needle was left in 
place for an additional 1 min. The needle was then slowly 
withdrawn and the incision closed. Tumor cell growth 
was monitored twice a week conducting quantitative 
bioluminescence imaging (qBLI) using the IVIS200 
imaging station (Caliper Life Sciences), beginning one 
week after tumor cell injection.
Bioinformatics analysis
Array analysis was performed using Matlab (The 
MathWorks Inc.). Signals were extracted using Agilent 
Feature Extraction, quantile normalized and log2-
trasformed. Paired and unpaired T-test were applied to 
evaluate significantly deregulated miRNAs. For signature 
selection we considered as significant pvalues less than 
0.01. A False Discovery Rate procedure (Storey, 2002) for 
multiple comparisons was also included in the analysis. 
Hierarchical Clustering and Principal Component Analysis 
were used to evaluate the efficacy of the selected signature. 
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